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Abstract
We present two results about using allele-count (AC) burdens of rare SNPs dis-
covered in a case-control sequencing study for prediction or validation in an external
prospective study. When genotyping only the SNPs polymorphic in the sequence data,
the phenotype to AC correlation tends to be larger in the replication data than the
primary study. Conversely, if the replication sample is sequenced, ACs of SNPs which
are novel in the replication tend to have much smaller or opposite signed associations.
We explain this by first deriving the AC-phenotype association implied by a model
of diverse SNP effects, and second accounting for the shifted distribution of SNP ef-
fects when using a case-control study as a filter for SNP inclusion. In rare diseases,
the case population is depleted of protective SNPs and enriched for deleterious SNPs,
creating the above difference in AC associations. This phenomenon is most relevant
in re-sequencing for risk prediction in rare diseases with heterogeneous rare mutations
because it applies to SNPs with MAF near 1 out of the case-control sample size and is
exaggerated when SNP log-odds ratios come from a heavy-tailed distribution. It also
suggests a “winner’s curse” in which most risk increasing SNPs at a particular MAF
are quickly discovered and future sequencing finds more protective or irrelevant SNPs.
1 Introduction
The increasing affordability of genome sequencing has seen caused many investigators
to look for rare variation underlying human disease. In response, gene-level association
tests for combining information from rare SNPs have become increasing well understood
and widely used. However, the replication of these associations and the role of rare SNPs
discovered in sequencing projects for estimation of risk has been less well defined in the
literature.
This paper considers the following hypothetical two-phase research program. In
phase one, a case-control study without substantial external data is conducted using
genomic sequencing over the gene (or region) of interest. In phase two, a prospective
replication sample is drawn from the same parent population without regard to pheno-
type. In phase two, genotypes are either assayed on the set of SNPs already found to
be polymorphic in phase one (custom genotyping) or assayed on all polymorphic SNPs
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in the gene (additional sequencing). We consider a very simple analytical approach to
this experiment and derive its properties; of course the analysis we focus on will not
be the most relevant for all possible investigators, but we argue below that it is well
suited to several goals. After phase one, the investigator estimates an overall associa-
tion between rare SNPs and phenotype using logistic regression of a per-person sum of
rare alleles versus phenotype, similar to an allelic burden test [1]. After the phase two,
we consider several options open to the investigator. First, she can predict phenotypes
using allele counts of the new participants and the associations implied by the phase one
data. Second, if the phenotypes of the new participants are known she can re-estimate
the allele-count association and quantitatively compare it to that in the old data in an
attempt to validate the association. Third, if additional sequencing is performed she
can estimate an allele-count association with the newly discovered (novel) SNPs and
compare it to that of the previously ascertained SNPs (those polymorphic in the phase
one data).
Why would an investigator do this? We argue that this analysis is relevant for
looking at very rare SNPs, especially those whose minor allele appears only a few
times in the data. Sequencing studies will continue to discover new rare SNPs for
the foreseeable future, and individuals sequenced for risk prediction will routinely carry
previously unseen and seldomly observed SNPs [2, 3]; detection of these rare SNPs is the
unique advantage of sequencing. While allele-count tests and their weighted relatives
are certainly not the most powerful tests in many circumstances, they do capture most
of the information contained in SNPs which appear only once in the data. Additionally,
tests and estimates of the mean SNP effect can be part of more complex procedures [4].
Predicted phenotypes and allelic burdens offer a transparent and intuitive approach to
validation of a prior finding. From a “personalized medicine” prediction perspective,
rare SNPs are a substantial contrast to GWAS with large samples and common SNPs;
we will never be in the comfortable position of having precise plug-in estimates for each
SNP. The best we can hope for with novel and seldomly observed SNPs is a pooled effect
estimate which extrapolates to new samples based on other SNPs in prior data in the
same gene. In particular, prediction from novel SNPs uses only information obtained
by borrowing from other SNPs. We will show that the optimal effect estimates for
prediction using previously polymorphic and novel SNPs are quite different. Finally,
associating novel SNPs by sequencing the phase two cohort offers a second form of
replication that the gene or subunit under study is important.
A crucial feature of our approach is that we think of the log odds-ratios (lORs) of
individual SNPs in a gene as coming from an incompletely observed group rather than
fixed unknowns which we want to infer. We also assume that lORs are heterogeneous
and described by a continuous distribution, but do not assume prior information on
which SNPs are likely to have large effect sizes. That is, our analysis treats them like
“random effects” rather than “fixed effects.” Our results are obtained by averaging
over both the generation of SNP lORs from an underlying distribution and sampling
of individuals from a population with SNP effects held fixed.
Based on the classical result that lORs are consistently estimated by both case-
control and prospective study designs [5, 6], one might anticipate that the disease-risk
to allele-count lOR for phase two genotyping, re-using the SNPs from the first phase
case-control study would coincide on average with parameter estimates from phase one.
However, we will show that the effect estimates from the two study designs are different
in expectation. One might also expect that the lOR for the count of novel alleles in
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phase two sequencing would be the same on average as that from phase one, or at least
the same direction. However, we show that the lOR for novel SNPs is often much less
or opposite signed.
2 Notation and Generative Models
N number of cases = number of controls
M number of SNPs in gene
i index for participants
j index for SNP
Yi participant outcome, 1= affected, 0=unaffected
Gij numeric genotype of person i at SNP j
gi count of rare alleles for person i, gi =
∑
j Gij
fj MAF of SNP j
K prevalence of disease
γj lOR of j
th SNP
µ E[γ] considering all SNPs in the gene
τ 2 Var[γ] considering all SNPs in the gene
µp E[γ|SNP polymorphic in primary study]
µr E[γ|SNP novel to replication study]
τ 2p Var[γ|SNP polymorphic in primary study]
τ 2r Var[γ|SNP novel to replication study]
βpa parameter of model (2), E[lOR Y vs g in primary study]
βra E[lOR] in replication using all SNPs (resequencing)
βrp E[lOR] in replication, only SNPs polymorphic in primary study
βrr E[lOR] in replication, only SNPs novel to replication study
Table 1: Notation
2.1 Generative and Descriptive Model
Denote the status of the ith individual in a study by Yi = 1 for diseased and 0 for
undiseased. In the phase one case-control study, assume an equal number N of diseased
cases and disease-free controls. Let G be a 2N ×M matrix of participant genotypes,
where Gij ∈ {0, 1} for the ith participant having either zero or one minor allele at the jth
locus, and Gi the row vector for the i
th participant. We ignore minor allele homozygotes
as they are uncommon at rare SNPs and complicate some of the expressions without
meaningfully changing the qualitative or the numerical results. To isolate the behavior
of SNPs at different minor allele frequencies (MAF), in all models, we fix all SNPs to
come from a common MAF f , which we will vary between scenarios.
We assume a generative model in which disease status arises via a vector of SNP-
specific effects γj . Specifically,
logit (Pr{Yi = 1|Gi, γ}) = Giγ + α , (1)
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where γj denotes the log-odds ratio of the j
th SNP, logit() is the logistic link function,
and α the intercept. In the population, the entire ensemble of SNP lORs are assumed
to arise as independent and identically distributed (IID) effects from a distribution
with mean E(γ) = µ and variance var(γ) = τ2; we will consider both Gaussian and
non-Gaussian distributions.
In phase one, the 2N individuals are sampled with equal probability from the af-
fected and unaffected. In phase two, we envision randomly drawing an individual from
the same larger population from which the initial case-control study was sampled; this
individual is equipped with a random draw Gi from the population of genotype vec-
tors. We keep the vector γ of SNP effects (lORs) the same between the case-control
and subsequent experiment; however, we do not carry over per-SNP inferences about
lORs (γˆ) from the case-control study to the prediction problem. The total population
is assumed large enough that re-sampling individuals is ignorable. We will show some
results at different phase one sample sizes, but we do not require it to be “small” in any
absolute way. We assume that phase one and two sample sizes are large enough that the
usual regression asymptotic results apply. Our results in phase two are averaged over
sampling new participants, and can be thought of as close to what one would obtain
with “large” samples.
We also define the allele-count burden model:
logit (Pr{Yi = 1|gi, β}) = giβ + a, (2)
where gi is a count of minor alleles. The burden model is descriptive, not generative for
the data, and some care is required in interpreting it. We intend to study “what one
would estimate,” but the estimated βˆ in a particular sample is both stochastic from
sampling of participants and a function of the realized SNP lORs, the number of SNPs
in the population, their MAF, and the sample size of the case-control study (as we will
show). We will show some results in the Supplement for particular realizations, but to
avoid dependence on sampling variation we will refer to the “true” β as the expected
value Eγ
[
Esampling Y, G
[
βˆ|Y,G, γ
]
|µ, τ
]
where the expectation is over both generation
of γ from its distribution and selection of participants from the larger population.
We operationalize the “rare SNP effect” as the lOR βpa obtained by regressing the
disease status versus the number of rare alleles in a primary case-control sequencing
study using all available SNPs (superscript for study design, subscript for SNP type),
and contrast it to the effect observed in future cohort replication or prediction samples
using all SNPs βra, only SNPs polymorphic in the primary study β
r
p, and only SNPs
novel to the replication study βrr . We adopt the same subscript conventions for the
moments of the distribution of γ; µ and τ are always the mean and standard deviation
of SNP effects in the entire population; the mean of lORs for those SNPs sampled in a
primary case-control study is µp, and those novel in a replication µr.
We refer to a test of β = 0 as an allele-count test ; for example a t-test of the number
of minor alleles between cases and controls.
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3 Results
3.1 Allele-count effects are generally non-zero
We begin by finding the regression association β in equation (2) implied by our random
effect model for γ in a prospective cohort study design when using all SNPs.
First, re-write the logistic model (1) as the equivalent latent liability model,
Pr{Yi = 1|Gi, µ, τ} = EγEi [I (i +Giγ > c|γ)] (3)
where i is a latent variable following a logistic distribution, I() the indicator function,
c = −log( K1−K ) ≈ −log(K) is the threshold value for the prevalence K of the disease
among those with no rare alleles, and subscripts on E denote random variables over
which expectation is computed. Next, approximate the logistic variable by a Gaussian
scaled by 1.6 [7]. Utilizing the IID Gaussian assumption of γj , a scalar sum gi is
sufficient for vector Gi, yielding
Pr{Yi = 1|Gi, µ, τ} ≈ PrZi{Zi
√
1.62 + τ2gi + µgi > c|gi},
where Zi is a standard normal. Re-apply the Normal-logistic approximation to obtain
Pr{Yi = 1|Gi, µ, τ} ≈ Pr∗i
{
∗i +
µgi − c√
1 + τ2gi/1.62
> 0
}
,
where ∗i is again logistic distributed. Finally, returning to a logistic regression form,
logit (Pr{Yi = 1|Gi, µ, τ}) ≈ logit (Pr{Yi = 1|gi, µ, τ}) ≈ −c+ µgi√
1 + τ2gi/1.62
(4)
Expression (4) is non-linear in gi; therefore, in any logistic-linear approximation,
β will depend on the distribution of gi. Although there is no “typical” distribution
of gi, we focus on cases where for most individuals it is small, and therefore present
calculations where β reflects the contrast/difference between gi = 1 and gi = 0. In that
context, approximation (4) can be manipulated to obtain,
β ≈ µ+ c(
√
1 + τ2/1.62 − 1)√
1 + τ2/1.62
. (5)
Contrasts at alternative values of gi can be obtained trivially.
The quality of approximation (5) depends on disease prevalence because of the
tails of the logistic and Gaussian distributions differ; it is acceptable for prevalence
(K) greater than 5%, (see Figure S1). The β in approximation (5) is a function of
the moments of SNP lORs included into G and g; as long as the distribution of γ
approximates a Gaussian it applies equally well to any of the β parameters in Table 1.
Because we are interested only in rare alleles, in most of our simulation settings
(described in the Supplement) most SNPs are sampled a small number of times and gi
is also small (often 0 or 1). As a result individuals are nearly independent of one another,
and the mis-specification created in equation (2) by not considering the covariance of
Y is minor, and the only practically detectable effect of the gene will be the shift in
the mean trait value, in contrast to many current sequencing analysis methods which
estimate or test the covariance of individuals created by SNP effects [8, 9, 10, 4].
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Expression (5) is linear in the log-prevalence and mean of SNP lORs and non-linear
in the variance of SNP lORs. In generative model (1), the absence of allelic effects,
i.e., γj = 0 for all j, will clearly yield no association between either Gi or gi and Yi.
We contrast this strong null hypothesis of no association with the weaker hypothesis
wherein the mean effect µ = 0, but the variance τ2 of effects is positive. In this latter
case, the non-linearity of (4) in gi gives rise to non-zero effects of allele counts.
To better illustrate these findings, we present numerical calculations in Figures 1,
2, 3, which jointly display results from this section and the next. All three figures are
obtained by numerical integration of equation (3) rather than approximation (5) and
show β parameters contrasting gi = 0 vs gi = 1. The left panels and dashed or dotted
curves are obtained using results from Section 3.3 and discussed there. The solid curve
of the right panel of Figures 1, 2, 3 display the βpa implied by equation (3) varying
(respectively) the prevalence, mean, and standard deviation of SNP lORs.
Figure 1 right panel shows that with symmetric but fairly variable SNP lORs (mean
0, SD 0.6) and uncommon to rare diseases (prevalence less than 5%) SNP allele counts
predict disease status with a non-trivial but small effect sizes (OR 1.15 - 1.20 per
allele). At higher prevalences the allele count lOR decreases proportionally with the
negative log of prevalence; at lower values it reaches a plateau. As mentioned above,
the discordance between Figure 1 and approximation (5) (the plateau) is due to the
failure of a Gaussian approximation of the tails of a logistic distribution. Figure 2
shows that, as one would anticipate, a non-zero average of SNP lORs is a main driver
of the expected burden lOR; the two are linearly related with a coefficient just slightly
off unity and an offset described in Figure 1. Figure 3 shows the SD of SNP lORs to
be another major determinant of βpa. Notably, β
p
a is zero when µ and τ are zero, that
is, under the null hypothesis than no SNPs have any effect. However, when τ > 0, βpa
is generally positive even if µ = 0, increasing quadratically with τ . Large values of βpa
with µ = 0 are only generated with fairly large values of τ ; for example, a per-allele
OR of about 1.5 is found with τ ≈ 1.0, meaning that the median absolute SNP OR is
near 2.0.
In a brief simulation study, we validate the theoretical results in equation (3) and
Figures 1, 2, 3. We simulate large cohorts varying each of the parameters (µ, τ, c and
the mean of gi) and tabulate the realized disease status by g; Tables S1 - S4 display
the results, which are in agreement with the Figures. The complete specification of the
simulation details is found in the Supplement.
Figure S5 takes a slightly different approach and instead illustrates that the power
of a t-test of allele counts (a) is non-trivial when the mean lOR is zero and the variance
is non-zero (b) increases markedly with the variance of lORs.
3.2 SNP ascertainment in case-control studies
Having obtained the regression association for all SNPs at a given MAF, we turn to
burden lORs in phase two’s replication cohort with either (a) the set of SNPs detected
as polymorphic (custom genotyping) or (b) novel SNPs in the same gene (sequencing).
The key to understanding our results is that the probability of passing the filter
“was the SNP polymorphic in phase one?” depends on the odds-ratio of that SNP.
Compared to prospective designs, case-control studies are somewhat more efficient for
discovering rare risk-increasing SNPs than risk-decreasing SNPs [11, 12, 13, 13, 14, 15]
since frequency among the cases is an increasing function of the OR. The set of SNPs
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Figure 1: Expected lOR and β in prospective and case-control studies versus
baseline disease prevalence. Left panel (discussed in Section 3.3): mean of previously
polymorphic SNP lORs µp (dashed) and novel SNP lORs µr (dotted) versus disease preva-
lence. Right panel: expected burden lORs βra = β
p
a (solid) versus prevalence (logarithmic
x-axis), and from Section 3.3 βrr (dotted), β
r
p (dashed). τ = 0.6, µ = 0, N=100, f = .005.
Prevalence defined among those with no rare minor alleles. Curves obtained by numerical in-
tegration of the distribution of SNP effects given polymorphic status using equations (6)-(7)
and numerical integration of marginal effect using equation (3).
which are polymorphic in phase one will therefore have a modestly positively deviated
mean lOR compared to the set of all SNPs in the gene, and the set of SNPs not
polymorphic in phase one (and therefore eligible to be novel in phase two) will have a
modestly downward deviated mean lOR. Therefore, for these selected populations of
SNPs the correct µ and τ in equation (3) and (5) must be modified to reflect the filtered
set of SNPs.
We can make this insight more rigorous. With trivial algebra, the probability of
exposure to a minor allele of SNP j among the controls and cases in a primary study is
Pr{Gij = 1|i ∈ controls}−1 = 1 + 1− fj
fj
(1−K +K ·ORj) (6)
Pr{Gij = 1|i ∈ cases}−1 = 1 + 1− fj
fj
(
1−K
ORj
+K
)
, (7)
where fj is the MAF of the j
th SNP, K the disease prevalence among homozygotes
with the major allele, and ORj = e
γj the odds-ratio. When both fj << 1 and K << 1
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Figure 2: Expected lOR and β in prospective and case-control studies versus mean
lOR. Left panel: µr (dotted) and µp (dashed) versus µ. Right panel: β
r
r (dotted), β
r
p (dashed)
and βra = β
p
a (solid) versus µ. Prevalence 5%, τ = 0.6, N=100, f = .005. Curves obtained
by numerical integration of the distribution of SNP effects given polymorphic status using
equations (6)-(7) and numerical integration of marginal effect using equation (3). Faint gray
line of identity
the expressions can be approximated by
Pr{Gij = 1|i ∈ controls} ≈
(
1 +
1 +K ·ORj
fj
)−1
≈ fj (8)
Pr{Gij = 1|i ∈ cases} ≈
(
1 +
1−K
ORj · fj
)−1
≈ ORj · fj . (9)
With the same assumption that the MAF and disease prevalence are low, the probability
that a given SNP j is observed at least once (i.e., is ascertained as polymorphic) in either
the N cases or N controls of phase one can be obtained using a Poisson approximation:
Pr
{∑
i
Gij > 0
}
≈ 1− exp(−fj N(1 +ORj)). (10)
There are three important things to note about formula (10). First, risk-associated
alleles are enriched into the case-sample, but the enrichment of disease-preventing alleles
into the control-sample is negligible in a rare-disease setting. Examining Equation (6),
one can see that decreasing the odds ratio from one to zero only slightly changes the
probability of exposure in controls when 1 − K >> K; however, the probability of
exposure in cases goes to zero almost linearly. Figure 4 displays the ratio and the
difference of polymorphic probabilities for risk-increasing versus risk-decreasing alleles
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Figure 3: Expected lOR and β in prospective and case-control studies versus SD
of lORs. Left panel: µr (dotted) and µp (dashed) versus τ . Right panel: β
r
r (dotted), β
r
p
(dashed) and βra = β
p
a (solid) versus τ . Prevalence 5%, µ = 0, N=100, f = .005. Curves
obtained by numerical integration of the distribution of SNP effects given polymorphic status
using equations (6)-(7) and numerical integration of marginal effect using equation (3).
with the same magnitude log-odds ratio; the risk-increasing allele is more likely to be
sampled for all MAFs and magnitudes of lOR.
Figure 4 displays the effect of retrospective sampling on fixed lORs, but it is more
natural to consider lORs which come from a continuous distribution. Figure 5 shows
the expected value of previously observed and novel lORs in a replication or prediction
sample (that is, µp and µr) for several members of the truncated Gaussian and Student’s
t distribution family. The right panel of Figure 5 displays an interesting consequence
of the above facts. Risk increasing alleles are increased in the case sample and total
likelihood of being observed and protective alleles are depleted; failing to discover a
SNP with MAF > 1/N suggests that this SNP has low frequency among cases and
is protective. However, as MAF increases the rate of non-polymorphic SNPs becomes
very low, and this feature is of little practical importance.
Distributions with heavier tails than a Gaussian exhibit a higher bias and an exag-
gerated effect at very low MAF. The cumulative distributions plots of the lORs under
these scenarios are displayed in Figure S6, which shows that they are very similar in
the region of zero and primarily differ in the likelihood of large uncommon lORs which
“rescue” occasional low-MAF SNPs into the case sample.
Second, due to the exponential form of formula (10), the above bias is meaningful
only for a narrow range of MAF and peaks for SNPs with MAF ≈ 1/2N . Common
minor alleles are virtually assured of being polymorphic in phase one, so the impact
of differential ascertainment becomes of negligible magnitude. As shown in the right
panel of Figure 4 the difference between sampling probabilities also goes to zero for
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Figure 4: Sampling probabilities by OR and MAF x-axis: N · f . Left panel y-axis:
ratio of sampling probability for a SNP at the implied MAF with OR given by the label to
the sampling probability under the inverse of that OR. Right panel: corresponding difference
in sampling probabilities. N=100, prevalence=1%.
Figure 5: µp (left) and µr (right) versus MAF by tail behavior of distribution of
SNP lORs. x-axis: N · f . y-axis: mean lOR. Source log-odds ratio distributed N(0,0.62)
(black), Student’s t distributions with 1, 2, 3 degrees of freedom (green, red, blue) truncated
at ±4 with same 20% and 80% quantile as N(0,0.62). N=100, prevalence=1%.
10
very low allele frequencies; even a quite large OR does not include many very rare
SNPs in the observed set. In Figure S2, the variance of polymorphic SNP lORs varies
with MAF; however, the change is small in the Gaussian case and only notable for
t distributions which allow large SNP effects and only for comparatively rare SNPs.
Previously observed SNPs (left panel Figure S2) have elevated variances for low MAF,
while novel SNPs have a small nadir in the variance around f ≈ 1/2N for the examined
t distributions. Intuitively, case-control sampling allows rare SNPs with quite large
effects to be sampled into the cases, increasing the variability of observed lORs.
Third, the polymorphic probability in formula (10) depends on the sample size,
rather than just the minor allele frequency. Above we argued that non-representative
sampling can only be a problem for a particular range of low to rare frequencies; how-
ever, that range is a function of the sample size. This creates a differential bias between
the SNP sets observed in studies of different sample sizes and ensures that as long as
there are low MAF SNPs the above bias will exist regardless of the sample size. In Fig-
ure S4 we recreate Figure 5 but with an increased sample size, which shifts the location
of the curve but leaves the shape the same. Finally, a feature lost in approximation
(10) is the dependence on baseline disease prevalence. Examining the probabilities in
Equation 7, as the prevalence goes to zero the enrichment of risk increasing SNPs in
cases is maximized. This is also illustrated in Figure 1.
3.3 Allele count lORs in phase two
Exploiting the foregoing results, the left-hand panels of Figures 1, 2, and 3 display the
mean lOR in the phase two study for previously polymorphic (µp) and novel (µr) SNPs
derived using equations (6)-(7). Using the results from Section 3.1 (equations (3) - (5)),
the right-hand panels of those figures then display the allele count lOR expected for
each group of SNPs in phase two.
The left panel of Figure 1 shows that previously sampled and novel SNPs have
notably different mean lORs, µp > µr and that this difference increases linearly as
the prevalence becomes small. The right panel similarly shows that the burden lOR is
markedly different between previously polymorphic and novel SNPs for rare diseases,
and that the difference decreases greatly as the prevalence goes from 1% to 15%. Figure
2 takes the same strategy varying the mean SNP effect µ. The difference in true means
of lORs and burden lORs between previously polymorphic and novel SNPs does change,
but not much within the plausible range of µ. Figure 3 again shows the variance of SNP
lORs to be a primary determinant of the difference in β. The difference in all β’s is zero
at τ = 0 (the null), but increases quickly with τ , especially beyond 0.5. Interestingly,
the change in β’s with τ does not quite mirror the change in µ’s with the burden lOR
for SNPs novel to the replication nearly constant around zero despite large negative
changes in the mean lOR of those SNPs.
To illustrate the variation within samples and the effect when SNP lORs are fixed,
a scatter plot of βˆrp and βˆ
r
r versus βˆ
r
a from simulations (described below) is shown in S3.
The estimated effects are always βˆrr < βˆ
r
a < βˆ
r
p, and the three highly correlated across
realizations of γ.
We validate these calculations in a second brief simulation study. In each simula-
tion, we draw a balanced case-control sample from a large population as well as an
independent prospective replication cohort; details of the simulation setup are found in
the Supplement and the results in Tables S5, S6, S7, S8, S9, S10, and S11. The tables
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recapitulate the claims above along with some new findings. In specific, the correct pre-
diction for previously observed SNPs is that they are much more risk increasing than
novel SNPs. As the mean or variance of SNP effects increases, the difference becomes
exaggerated (Tables S7 and S6). With MAFs which are small compared to the sample
size, previously observed SNPs are more risk-increasing and at larger MAFs novel SNPs
are very protective (Table S8 and S10). The sample size determines the MAF at which
the difference in SNP classes is largest, but not the maximum magnitude of the effect
(Table S10 and S9).
4 Discussion
Our findings can be summarized around two central points. First, we clarify the factors
which affect the expected lOR of allele-count burdens, and find that they are not an in-
tuitive reflection of the SNP-specific model which generates the data. The allele-count
to phenotype correlation is determined by the variance of SNP effects and disease preva-
lence as well as the mean lOR of SNPs. We focus on the case where the mean log-odds
ratio is zero and provide examples in hypothesis tests (Figure S5) and prediction (Fig-
ure 3) where an investigator could correctly claim than possessing more minor alleles
increased risk of disease. The differing interpretation of the mean effect of increasing
allele-counts and the mean of SNP lORs is a product of the asymmetric baseline risk of
being affected with disease and the nonlinear nature of logistic models of risk. An in-
creased variance of SNP lORs will change the disease risk for those individuals carrying
rare alleles in both directions; however, there are many more undiseased individuals at
risk of becoming diseased than vice versa, so increasing positive and negative lORs do
not cancel out in their effects on the population.
Second, we show that replication experiments which selectively genotype rare SNPs
previously observed in a case-control study will tend to find a larger allele count lOR
than in the primary study. The complementary set of SNPs (those not seen in the
primary case-control sample and novel to the replication experiment) tend to increase
risk less than average or even decrease it; further sequencing to find more rare SNPs will
experience a unique “winner’s curse” as shown in Figure 3. A different application of the
same finding is that novel alleles in highly associated genes in individuals sequenced
for medical prediction tend to carry much less risk than the SNPs in a case-control
discovery study. This can be understood by considering the impact of SNP lOR on
the likelihood of a SNP being polymorphic in a case-control study. Risk-decreasing
minor alleles have an decreased frequency among cases compared to their population
MAF and are more likely than SNPs which increase risk to be observed zero times
in the study; these low-impact and negatively associated SNPs have been filtered out.
Further data collection which uses a case-control study to select SNPs to genotype
is therefore partially conditioning on the effect size of those SNPs. This difference
between previously observed and novel SNPs is mostly observed at MAF near 1/2N ,
and therefore predictions based on experiments of different size can appear inconsistent.
We have represented SNP lORs using a continuous distribution. This is not a prior
uncertainty like in a Bayesian analysis. From gene to gene, we can expect the realized
distribution of SNP effects to vary even if there is no fundamental difference in the
propensity for SNPs in that gene to affect the trait. Similarly, within a gene we foresee
substantial variation in realized rare SNP lORs across human populations with SNPs
12
private to their ancestry and by sampling variation within human populations (for
example between the initial association study and a replication cohort).
We have represented SNP lORs using a continuous distribution. This is not a prior
uncertainty like in a Bayesian analysis. From gene to gene, we can expect the realized
distribution of SNP effects to vary even if there is no fundamental difference in the
propensity for SNPs in that gene to affect the trait. Similarly, within a gene we foresee
substantial variation in realized rare SNP lORs across human populations with SNPs
private to their ancestry and by sampling variation within human populations (for
example between the initial association study and a replication cohort).
These findings are preceded by several related ideas in the biostatistics literature.
In the terms of the causal inference literature, predictors in logistic model are not
“collapsible” [16]. While it has been observed that a SNP specific (random effect)
model is richer and answers additional questions, the parameters can have an awkward
interpretation and extrapolation to new data, as we have observed. This distinction
originated in biometrics modeling longitudinal data [17], but has been reiterated in
many contexts [18, 19, 20, 21].
Coming from different perspectives, many previous authors have noted that com-
pared to prospective designs, case-control studies are somewhat more efficient for dis-
covering rare risk-increasing SNPs [11, 12, 13, 13, 14, 15], generally taken as an argu-
ment increasing the power of case-control study. There is also a related literature on
ascertainment-adjustment to variance components based analysis of family data, which
stems from a similar problem [22, 23, 24, 25, 26, 27, 28, 29, 30]. In family designs the
relatively simple structure of ascertainment makes correction feasible. Similarly, SNP-
panel and small sequencing study based inferences on site frequency spectra and other
population genetic quantities have been examined for ascertainment bias [31, 32, 33].
An important limitation to our results is that the calculations only produce sub-
stantial bias in the presence of fairly strong SNP effects (Figures 3 and 5), which might
be unrealistic. However, the supposed existence of rare SNPs with large effects is a
major rationale for performing sequencing-based association studies [34], and that the
failure to detect such variants in GWAS does not exclude their existence. We suspect
that a distribution like the truncated Student’s t used in Figure 5 whose distribution
is plotted in Figure S6 represents a reasonable belief about log-odds ratios in causal
genes; most are very nearly zero with a few outlying strong effects.
A second limitation of these findings is that they ignore external data on SNP
MAF. With numerous sequencing projects published and in development, “discovery”
of SNPs during future case-control projects may be very limited, and the information
on MAF provided by external data should stabilize per-SNP inferences about ORs.
However, because of the human SNP site-frequency spectrum, additional sequencing is
predicted to continue discovering new SNPs for quite some time [2, 3]. Additionally,
existing panels such as 1000 genomes do not provide much MAF information for SNPs
unique to unincluded populations such as Native Americans, and population isolates
of interest to particular diseases can have markedly different MAFs due to drift as
well as private SNPs. Finally, many non-human organisms do not yet have extensive
sequencing catalogs, but their genetics are of scientific and applied importance and
investigated by similar scientific methods.
Third, we have not presented simulations or calculations where MAFs are drawn
from a continuous distribution as they would be in real data. Because the difference
between primarily polymorphic and novel in replication SNPs varies with MAF, we
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feel that such scenarios add an unnecessary level of complication to understanding the
phenomenon without creating additional insight. Approximate results for a mixture of
MAFs can be obtained by a weighted average of the results for point distributions of
MAF. Uncommon SNPs (especially singletons) observed in a real sequencing study are
a mixture of those with MAF near 1/2N and lucky representatives of the large pool of
rarer SNPs. Fortunately, as seen in Figures 4 and 5 the relative bias stabilizes as the
MAF becomes small. The impact of MAF is still important to keep in mind because
comparisons across genes with different SNP frequency spectra will experience differen-
tial bias. Similarly, there will be differential bias when comparing human populations
with different demographic history and therefore SNP frequency distributions [35].
We have reserved study of methods for correction of the ascertainment effects of
section 3.3 for future work. Calculating the bias for known distributions of MAF and
SNP effects is trivial; however, applying this correction in practice is challenging for
several reasons. First, as we showed in Figure 5 the result depends on the tails of
the distribution of lORs, which can be difficult to accurately estimate. Second, the
observed data are minimally informative for estimation of the MAF spectrum around
1/2N and especially for extrapolation to lower MAF. External information in the form
of demographic models and previously sequenced cohorts of the same ethnicity will be
crucial to developing accurate estimates and can not be spoken to in much generality.
Third, the joint distribution of MAF and SNP lORs matters. We have performed
calculations only where the two are independent, but if the two are correlated, as
models of phenotype selection imply [4], then a more complex procedure is required
which estimates the distribution of SNP effects for low MAFs and extrapolates to very
low MAFs.
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Supplement
Figure S1: Comparison of formulas (5) and (3). Disease prevalence among those with no
minor alleles (x-axis) versus burden lOR from equation (3) (dotted) and formula (5) (solid).
lOR of 1 SNP versus 0 SNPs. SD of SNP lORs 0.6, mean of lORs 0, MAF 0.005. Low limit
of plot = 0.001.
4.1 Simulation settings
For Figure S5 we simulated 40 SNPs with minor allele frequencies drawn from a beta
distribution mean .12 standard deviation .02 in a population of 1 million individuals
with a baseline disease prevalence of 5%, drawing a sample of 500 cases 500 controls
for each of the depicted values of the standard deviation of log-odds ratios. Log odds-
ratios were always mean zero IID normal. We then conducted a t-test of the number
of minor alleles in cases and controls; essentially identical results were obtained for
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Figure S2: τp (left) and τr (right) versus MAF by tail behavior of distribution of
SNP lORs. Settings identical to Figure 5.
rank-tests and generalized linear models. 2000 replicates for each point in each figure
were produced, each repeating the entire procedure.
Tables S1-S11 use a Gaussian distribution for lORs and a large sample prospective
(106) generated by the logistic model (1) with all SNPs uncorrelated. 2000 replicates
are drawn for each Table. Table S1 varies the disease prevalence in rows and holds the
SD of SNP effects at 0.6, the mean SNP effect at 0, the MAF at 0.01, and the number
of SNPs at 50. Table S2 varies the SD of SNP effects in rows and holds the the mean
SNP effect at 0, the disease prevalence at 5%, the MAF at 0.01, and the number of
SNPs at 50. Table S3 varies the mean of SNP effects in rows and holds the SD of SNP
effects at 0.7, the disease prevalence at 5%, the MAF at 0.01, and the number of SNPs
at 50. Table S4 varies the SNP MAF in rows and holds the SD of SNP effects at 0.7,
the mean SNP effect at 0, the disease prevalence at 5%, and the number of SNPs at
50. Tables for retrospective simulation draw 100 cases and 100 controls from a source
population of 106 and compare the results in 106 future independent individuals. We
display only the contrast for having no minor alleles versus 1 minor allele for all alleles
combined, novel in follow-up, and previously discovered SNPs; patterns in the impact
of the number of alleles are similar to the prospective case (not shown). Table S5 varies
the disease prevalence in rows and holds the SD of SNP effects at 0.6, the mean SNP
effect at 0, the MAF at 0.01, and the number of SNPs at 50. Table S6 varies the SD
of SNP effects in rows and holds the the mean SNP effect at 0, the disease prevalence
at 5%, the MAF at 0.01, and the number of SNPs at 50. Table S7 varies the mean of
SNP effects in rows and holds the SD of SNP effects at 0.7, the disease prevalence at
5%, the MAF at 0.01, and the number of SNPs at 50. Table S8 varies the SNP MAF
in rows and holds the SD of SNP effects at 0.7, the mean SNP effect at 0, the disease
prevalence at 5%, and the number of SNPs at 50. Table S9 jointly varies the number
of SNPs and the MAF to keep the average number of minor alleles per person at 0.5; it
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Figure S3: βˆrp (red) and βˆ
r
r (blue) vs βˆ
r
a (x-axis position). Black line identity. Prevalence 1%,
MAF .005, mu = 0, τ = 0.6, N=100, 35 SNPs, total population size 107, prediction cohort
N = 106.
holds the SD of SNP effects at 0.7, the mean SNP effect at 0, and the disease prevalence
at 5%. Table S10 varies the case-control sample size in rows and holds the SD of SNP
effects at 0.7, the mean SNP effect at 0, the disease prevalence at 5%, the MAF at 0.01,
and the number of SNPs at 50. Table S11 jointly varies the MAF and the sample size
in rows to keep the expected number of appearances for each SNP constant at 0.5; it
holds the SD of SNP effects at 0.7, the mean SNP effect at 0, the disease prevalence at
5%, and the number of SNPs at 50.
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1 2 3
0.2 0.09 0.09 0.16 0.17 0.22 0.23
0.1 0.14 0.13 0.26 0.24 0.35 0.33
0.05 0.19 0.15 0.34 0.28 0.48 0.40
0.01 0.29 0.18 0.54 0.33 0.74 0.48
Table S1: lOR of outcome by number of derived alleles (log odds of disease given g = column
index - log odds given g = 0) from formula (5) (left number) and simulation (right number)
varying prevalence of disease (first column). Prospective sampling design..
1 2 3
0.25 0.04 0.03 0.07 0.05 0.10 0.07
0.5 0.13 0.10 0.25 0.20 0.35 0.28
0.75 0.28 0.23 0.49 0.42 0.66 0.57
1 0.45 0.38 0.74 0.65 0.95 0.85
1.25 0.62 0.55 0.97 0.89 1.19 1.11
Table S2: lOR of outcome by number of derived alleles (log odds of disease given g = column
index - log odds given g = 0) from formula (5) (left number) and simulation (right number)
varying SD of SNP effects (first column). Prospective sampling design.
Figure S4: Effect of increasing sample size on ascertainment bias. Identical to right
panel of figure 4 with new lines displaced to the left the result with N=1000 instead of N=100.
X-axis = 100 · f .
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1 2 3
-0.47 -0.18 -0.25 -0.36 -0.52 -0.53 -0.79
0 0.25 0.21 0.44 0.38 0.60 0.52
0.26 0.49 0.46 0.89 0.86 1.22 1.21
0.47 0.68 0.66 1.24 1.24 1.72 1.74
0.69 0.88 0.87 1.62 1.62 2.26 2.25
0.92 1.09 1.08 2.00 2.01 2.79 2.80
Table S3: lOR of outcome by number of derived alleles (log odds of disease given g = column
index - log odds given g = 0) from formula (5) (left number) and simulation (right number)
varying mean of SNP effects (first column). Prospective sampling design.
1 2 3
0.005 0.25 0.20 0.44 0.37 0.60 0.51
0.01 0.25 0.19 0.44 0.36 0.60 0.49
0.02 0.25 0.21 0.44 0.38 0.60 0.52
0.03 0.25 0.20 0.44 0.37 0.60 0.51
0.05 0.25 0.20 0.44 0.37 0.60 0.51
Table S4: lOR of outcome by number of derived alleles (log odds of disease given g = column
index - log odds given g = 0) from formula (5) (left number) and simulation (right number)
varying SNP MAF (first column). Prospective sampling design.
all novel old
0.2 0.10 0.10 -0.01 -0.00 0.15 0.16
0.1 0.13 0.14 -0.02 -0.00 0.21 0.22
0.05 0.16 0.16 -0.02 -0.00 0.24 0.25
0.01 0.17 0.18 -0.03 -0.00 0.27 0.28
0.001 0.18 0.19 -0.03 -0.00 0.27 0.29
1e-04 0.18 0.19 -0.03 -0.00 0.27 0.29
Table S5: lOR of outcome by SNP class for first allele from formula (5) (left number) and
simulation (right number) varying prevalence of disease (first column). Case-control sampling
design.
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Figure S5: Standard deviation of log-odds ratios (x-axis) and simulated power of t-test of
allele count (y-axis) in case-control design when the log-odds ratios are Gaussian with mean
zero, N=500, prevalence .05, 40 SNPs, MAF drawn from a beta distribution with mean .12
and SD .02, 2000 replicates.
all novel old
0.25 0.03 0.02 -0.03 -0.02 0.03 0.03
0.5 0.11 0.10 -0.11 -0.09 0.14 0.12
0.75 0.24 0.21 -0.23 -0.18 0.29 0.26
1 0.40 0.35 -0.36 -0.28 0.48 0.43
1.25 0.58 0.52 -0.49 -0.37 0.68 0.61
Table S6: lOR of outcome by SNP class for first allele from formula (5) (left number) and
simulation (right number) varying SD of SNP effects (first column). Case-control sampling
design.
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Figure S6: Cumulative distribution plots for SNP log-odds ratios used in Figure 5.
N(0,.62) (black), Student’s t distributions with 1, 2, 3 degrees of freedom (green, red, blue)
with same inner 80% quantile as N(0,.62).
all novel old
-0.47 -0.25 -0.28 -0.56 -0.52 -0.20 -0.23
0 0.21 0.18 -0.20 -0.16 0.26 0.23
0.26 0.46 0.44 -0.01 0.04 0.51 0.48
0.47 0.66 0.64 0.13 0.20 0.70 0.67
0.69 0.87 0.85 0.28 0.39 0.91 0.88
0.92 1.09 1.07 0.43 0.58 1.11 1.09
Table S7: lOR of outcome by SNP class for first allele from formula (5) (left number) and
simulation (right number) varying mean of SNP effects (first column). Case-control sampling
design.
all novel old
0.005 0.21 0.18 -0.03 -0.02 0.32 0.28
0.01 0.21 0.18 -0.20 -0.16 0.26 0.23
0.02 0.21 0.18 -0.44 -0.32 0.22 0.19
0.03 0.21 0.18 -0.62 -0.49 0.21 0.18
0.05 0.21 0.18 -0.88 -0.75 0.20 0.18
Table S8: lOR of outcome by SNP class for first allele from formula (5) (left number) and
simulation (right number) varying SNP MAF (first column). Case-control sampling design.
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all novel old
0.005 0.21 0.19 -0.03 -0.02 0.32 0.29
0.01 0.21 0.18 -0.20 -0.16 0.26 0.23
0.02 0.21 0.16 -0.44 -0.31 0.22 0.17
0.03 0.21 0.15 -0.62 -0.46 0.21 0.15
0.05 0.21 0.12 -0.88 -0.65 0.20 0.12
Table S9: lOR of outcome by SNP class for first allele from formula (5) (left number) and
simulation (right number) varying MAF and number of SNPs with constant expected count
per person (first column). Case-control sampling design.
all novel old
50 0.21 0.20 0.07 0.08 0.37 0.32
100 0.21 0.20 -0.03 -0.02 0.32 0.29
200 0.21 0.20 -0.20 -0.17 0.26 0.25
500 0.21 0.20 -0.54 -0.43 0.21 0.20
1000 0.21 0.20 -0.87 -0.74 0.21 0.20
Table S10: lOR of outcome by SNP class for first allele from formula (5) (left number) and
simulation (right number) varying sample size (first column). Case-control sampling design.
all novel old
0.005 0.21 0.18 -0.03 -0.02 0.32 0.28
0.01 0.21 0.18 -0.03 -0.02 0.32 0.27
0.02 0.21 0.18 -0.03 -0.02 0.31 0.27
0.03 0.21 0.18 -0.03 -0.03 0.31 0.26
0.05 0.21 0.18 -0.03 -0.02 0.31 0.25
Table S11: lOR of outcome by SNP class for first allele from formula (5) (left number) and
simulation (right number) varying MAF and sample size with constant expected count per
SNP (first column = MAF). Case-control sampling design.
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